TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05290129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin will be prepared in a 1L bag of Ringer's lactate, to be infused at a rate of 125 ml/h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin will be prepared in a 1L bag of Ringer's lactate, to be infused at a rate of 125 ml/h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin will be prepared in a 1L bag of Ringer's lactate, to be infused at a rate of 125 ml/h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin will be prepared in a 1L bag of Ringer's lactate, to be infused at a rate of 125 ml/h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin will be prepared in a 1L bag of Ringer's lactate, to be infused at a rate of 125 ml/h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin will be prepared in a 1L bag of Ringer's lactate, to be infused at a rate of 125 ml/h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin will be prepared in a 1L bag of Ringer's lactate, to be infused at a rate of 125 ml/h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin will be prepared in a 1L bag of Ringer's lactate, to be infused at a rate of 125 ml/h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin will be prepared in a 1L bag of Ringer's lactate, to be infused at a rate of 125 ml/h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin will be prepared in a 1L bag of Ringer's lactate, to be infused at a rate of 125 ml/h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin will be prepared in a 1L bag of Ringer's lactate, to be infused at a rate of 125 ml/h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin will be prepared in a 1L bag of Ringer's lactate, to be infused at a rate of 125 ml/h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin will be prepared in a 1L bag of Ringer's lactate, to be infused at a rate of 125 ml/h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin will be prepared in a 1L bag of Ringer's lactate, to be infused at a rate of 125 ml/h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin will be prepared in a 1L bag of Ringer's lactate, to be infused at a rate of 125 ml/h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin will be prepared in a 1L bag of Ringer's lactate, to be infused at a rate of 125 ml/h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin will be prepared in a 1L bag of Ringer's lactate, to be infused at a rate of 125 ml/h.
Study: NCT04133935

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Obturator Urethropexy
Description: Suspending the periurethral vaginal tissue to the obturator internus fascia bilaterally via sutures, creating a support for the bladder neck compartment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Burch Urethropexy
Description: Suspending the periurethral vaginal tissue to Cooper's ligament bilaterally via sutures, creating a support for the bladder neck compartment
Study: NCT04939259

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New Music Program
Description: A mini behind-the-ear hearing aid that amplifies sounds and directs them into the ear. The music program within the hearing aid will provide amplification specifically tuned for listening to music.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: New Music Program
Description: A mini behind-the-ear hearing aid that amplifies sounds and directs them into the ear. The music program within the hearing aid will provide amplification specifically tuned for listening to music.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Listening Program
Description: A mini receiver-in-the-ear hearing aid that amplifies sounds and directs them into the ear. The standard listening program within the hearing aid will provide amplification specifically tuned for listening to speech and daily general sounds in the environment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Listening Program
Description: A mini receiver-in-the-ear hearing aid that amplifies sounds and directs them into the ear. The standard listening program within the hearing aid will provide amplification specifically tuned for listening to speech and daily general sounds in the environment.
Study: NCT04938037

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US guided, SSNB with 1ml methylprednisolone acetate (1ml / 40mg) and 5 ml 0.5% bupivacaine
Description: nerve block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US guided, SSNB with 1ml methylprednisolone acetate (1ml / 40mg) and 5 ml 0.5% bupivacaine
Description: nerve block
Study: NCT05035082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Oral administration The doctor will give a prescription for the medicine and tell how to take it.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral glucose-lowering medications (commercially available)
Description: Oral administration The doctor will give a prescription for the medicine and tell how to take it.
Study: NCT05319678

Intervention type: OTHER
Intervention: evaluation with Meludia music software
Description: Measurement instruments:~1. - MuMu Questionnaire~2. MuRQoL Questionnaire~3. Questionnaire for subjects aged 6-17 years~4. Music tool Meludia (www.meludia.com)~5. Acoustic analysis of the voice: the Praat programme~6. Audiological tests

Intervention type: OTHER
Intervention: evaluation with Meludia music software
Description: Measurement instruments:~1. - MuMu Questionnaire~2. MuRQoL Questionnaire~3. Questionnaire for subjects aged 6-17 years~4. Music tool Meludia (www.meludia.com)~5. Acoustic analysis of the voice: the Praat programme~6. Audiological tests
Study: NCT06087445

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroLife EMG-FES Sleeve System
Description: Participants will complete a 12-week training protocol (3x/week, 1-2 hours/session) which includes an activity-based upper extremity training paradigm where participants will complete multiple repetitions attempting functional tasks in different categories (grip, grip with rotation, pinch, and pinch with rotation) while using the closed-loop EMG-FES system on one forearm/hand. Each category includes \~10 functional tasks (e.g., grip - open a jar; pinch with rotation - nuts and bolts) that progressively increase in difficulty. Each session will include massed practice of 3 functional tasks (20-minute blocks for each task) with rest breaks as needed to avoid fatigue. Sessions will include \~60 minutes of task practice, but they may last 1-2 hours to account for setup time and rest breaks.
Study: NCT05810922

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: arbutus berry
Description: consumption of 50 g arbutus berry/day or 200 g arbutus berry/day for 14 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: arbutus berry
Description: consumption of 50 g arbutus berry/day or 200 g arbutus berry/day for 14 days
Study: NCT06573957

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Patient in experimental arms will received intravenous dexmedetomidine at a dose of 0.5 µg/kg body weight 10 minutes before general anesthesia induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocain
Description: Patient in experimental arms will receive intravenous lidocaine at 1.5 mg/kg body weight in a 5cc syringe 90 seconds before intubation
Study: NCT06396728

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GI BIOTICS 100B UFC
Description: Consumption of GI BIOTICS 100B UFC.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Consumption
Description: Consumption of a placebo capsule.
Study: NCT06384677

Intervention type: OTHER
Group type: OTHER
Intervention: M-Tapa Block
Description: M-TAPA block was performed bilaterally with 20 mL of 0.2% bupivacaine under ultrasound guidance at the end of surgery

Intervention type: OTHER
Group type: OTHER
Intervention: M-Tapa Block
Description: M-TAPA block was performed bilaterally with 20 mL of 0.2% bupivacaine under ultrasound guidance at the end of surgery
Study: NCT05241626

Intervention type: DIAGNOSTIC_TEST
Intervention: AS-OCT
Description: Optical Coherence Tomography (OCT) creates detailed cross-sectional images of the anterior and posterior segments using low coherence interferometry. OCT is a noninvasive, real-time method for evaluating the tear meniscus, total corneal thickness (CT), and corneal epithelial thickness

Intervention type: DIAGNOSTIC_TEST
Intervention: AS-OCT
Description: Optical Coherence Tomography (OCT) creates detailed cross-sectional images of the anterior and posterior segments using low coherence interferometry. OCT is a noninvasive, real-time method for evaluating the tear meniscus, total corneal thickness (CT), and corneal epithelial thickness
Study: NCT05410912

Intervention type: PROCEDURE
Intervention: Great saphenous vein stripping and ambulatory phlebectomy
Description: All patients included in the study were treated with great saphenous vein stripping and ambulatory phlebectomy.

Intervention type: PROCEDURE
Intervention: Great saphenous vein stripping and ambulatory phlebectomy
Description: All patients included in the study were treated with great saphenous vein stripping and ambulatory phlebectomy.
Study: NCT05660109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPM502
Description: TPM502 contains 3 peptides each consisting of two overlapping T cell epitopes that encompass the major gluten epitopes for HLA-DQ2.5

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05193994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir, Abacavir and Lamivudine
Description: Dolutegravir 50mg, Abacavir 600mg and Lamivudine 300mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo.
Study: NCT04725994

Intervention type: DRUG
Group type: OTHER
Intervention: IDX-1197+XELOX
Description: The dose levels will be escalated following a 3+3 dose escalation scheme.

Intervention type: DRUG
Group type: OTHER
Intervention: IDX-1197+Irinotecan
Description: The dose levels will be escalated following a 3+3 dose escalation scheme.
Study: NCT04960813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured games
Description: Camp Kidpower - Structured Games is an interactive, child-friendly camp and is comprised of short, game-like exercises taught by camp counselors to groups of approximately 4-6 children. In total, 15 different exercises will be taught. Children will attend 5 three-hour playgroup sessions over a 4-week period (twice the first week, and then only once per week for the subsequent 3-week period) to match the Playgroup intervention.~Parents will be asked to attend an approximately one-hour group meeting, during which information is presented regarding child anxiety, effortful control and the rationale for this treatment. Parents are asked to continue to utilize the intervention at home every day if possible with the child and will receive texts or emails to track the games that are played at home.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Playgroup
Description: Camp Kidpower - Playgroup includes structured play activities. This will include art activities, dramatic play props, and a story time. Children will attend 5 three-hour playgroup sessions over a 4-week period (twice the first week, and then only once per week for the subsequent 3-week period) to match the Kidpower intervention.~During the first week parents will attend an approximately one-hour group meeting, during which information is presented regarding the positive benefits of child-led play and special time with caregivers.~Parents well be asked to complete homework with their children during the week between sessions, and are shown how to track time spent in this activity. Parents will receive a daily text (or email) to to measure frequency of homework practice between sessions.
Study: NCT05086458

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics
Description: probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis
Study: NCT04734379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasudil
Description: Oral fasudil 180 mg/day
Study: NCT04161118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTL019
Description: IV Infusion
Study: NCT06043414

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: triclosan-coated barbed suture
Description: STRATAFIX™ Symmetric PDS™ (Johnson \& Johnson) triclosan-coated polydioxanone barbed suture caliber 0 or 1 will be the standardized suture used for abdominal fascial closure in patients randomized to the treatment group. STRATAFIX™ Symmetric PDS™ is an FDA approved sterile, synthetic, absorbable, barbed triclosan-coated polydioxanone suture. Its indications for use include soft tissue approximation where absorbable suture is appropriate.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: triclosan-coated non-barbed suture
Description: PDS™ Plus (Johnson \& Johnson) non-barbed triclosan-coated polydioxanone suture in either 0 or 1 caliber will be used for abdominal fascial closure in patients randomized to the control group. PDS™ Plus is an FDA approved sterile, synthetic, absorbable, triclosan-coated surgical monofilament suture prepared from the polyester, poly(p-dioxanone). Its indications for use include soft tissue approximation where absorbable suture is appropriate.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non-coated non-barbed suture
Description: PDS™ II (Johnson \& Johnson) non-barbed non-coated polydioxanone suture in either 0 or 1 caliber will be used for abdominal fascial closure in patients randomized to the control group. PDS™ II is a FDA approved sterile, synthetic, absorbable, surgical monofilament suture prepared from the polyester, polyester, poly(p-dioxanone) indicated for use in soft tissue approximation where absorbable suture is appropriate.
Study: NCT05294640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% Bacteriostatic Local Anesthetic Injection
Description: Following research and procedural consent, local anesthetic injection will be carried out using a standard 1 cc of local anesthetic corresponding to the study arm (0.9% bacteriostatic saline or 1% lidocaine with 1:100,000 epinephrine). Prior to anesthetic administration, the procedure site will be cleaned using standard measures. A 30 gauge needle on a 3 centimeter cubed volume syringe will be utilized. Five minutes will be given for local anesthetic to take effect.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Lidocaine with 1:100,000 epinephrine Local Anesthetic Injection
Description: Following research and procedural consent, local anesthetic injection will be carried out using a standard 1 cc of local anesthetic consisting of a commercially available mixture of 1% lidocaine with 1:100,000 epinephrine. Prior to anesthetic administration, the procedure site will be cleaned using standard measures. A 30 gauge needle on a 3 centimeter cubed volume syringe will be utilized. Five minutes will be given for local anesthetic to take effect.
Study: NCT06056531

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Near infrared light imaging
Description: The participant performing PVC carried out the procedure on the arm vein of another volunteer classmate with the help of vein imaging by NIR. All interventions were conducted under the observation of the researchers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric exercise with stress ball
Description: Before the procedure, the students on whom PVC was to be performed were given two stress balls, and they were told how to use them for 15 minutes. The participants were told to squeeze and relax the stress ball in the palm of their hands after counting from one to three, to continue doing this until the procedure began, and to concentrate on squeezing the ball.
Study: NCT05084807

Intervention type: OTHER
Group type: OTHER
Intervention: Endoscopy
Description: * A dyspepsia test will be performed to avoid selection bias. In subjects strictly asymptomatic, a blood analysis will be proposed.~* Subjects who present strictly normal laboratory tests (including celiac serology and negative H Pylori tests) and no genetic risk of celiac disease will be invited to perform an upper gastrointestinal endoscopy.~* During gastroscopy, samples of normal mucosa will be taken for histological and lymphocyte subpopulations analysis. The percentage of lymphocyte subpopulations will be assessed by flow cytometry.~* To compare whether there are differences between the lymphocyte subpopulations related to the age and sex of the healthy individuals, a student's t test, ANOVA or the corresponding non-parametric test will be used. The values will be expressed according to: mean +/- 2DS or median and interquartile range.
Study: NCT06346600

Intervention type: GENETIC
Intervention: SKG0106
Description: Non-interventional (observational) study, long-term follow-up safety and efficacy assessments up to 5 years post SKG0106 injection.

Intervention type: GENETIC
Intervention: SKG0106
Description: Non-interventional (observational) study, long-term follow-up safety and efficacy assessments up to 5 years post SKG0106 injection.

Intervention type: GENETIC
Intervention: SKG0106
Description: Non-interventional (observational) study, long-term follow-up safety and efficacy assessments up to 5 years post SKG0106 injection.
Study: NCT04916067

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mesh Implantation
Description: Implantation of Phasix™ Soft Mesh - a knitted monofilament mesh scaffold using Poly-4-hydroxybutyrate (P4HB), a biologically derived material - to prevent hernia formation
Study: NCT06565832

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One-Minute Sit-to-Stand Test
Description: This test involves sitting down and standing up from a normal height chair (can be a dining room or kitchen chair at home) for one minute. Participants can rest or stop at any time if fatigued. Participants will be asked to record your heart rate and oxygen levels before and after the test and will be given a monitor to do this with if they do not already have one. This test should take a maximum of 5 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One-Minute Sit-to-Stand Test
Description: This test involves sitting down and standing up from a normal height chair (can be a dining room or kitchen chair at home) for one minute. Participants can rest or stop at any time if fatigued. Participants will be asked to record your heart rate and oxygen levels before and after the test and will be given a monitor to do this with if they do not already have one. This test should take a maximum of 5 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chester Step Test
Description: This test involves the participant stepping up and down off of a step (this can be a bottom stair or doorstep at home) keeping up with the beat of a recording. The speed of the beat increases every 2 minutes, and the test continues until the participant cannot keep up with the pace, wish to stop or the test ends which takes 10 minutes. Participants will be asked to record heart rate and oxygen levels before and after the test. This test should take a maximum of 15 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chester Step Test
Description: This test involves the participant stepping up and down off of a step (this can be a bottom stair or doorstep at home) keeping up with the beat of a recording. The speed of the beat increases every 2 minutes, and the test continues until the participant cannot keep up with the pace, wish to stop or the test ends which takes 10 minutes. Participants will be asked to record heart rate and oxygen levels before and after the test. This test should take a maximum of 15 minutes.
Study: NCT04903717

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Best Practice Alert
Description: Providers randomized to the intervention arm will have a best practice alert appear for each of their eligible patients upon opening of the order entry screen in the patient's medical record. This alert informs the provider to the presence of HFrEF and absence of MRA prescription, notes the patient's current LVEF, and notes the most recent labs, including NT-ProBNP, potassium, and creatinine. Providers will also have access to a link to best available guideline recommended information regarding use of MRAs and a link to both an order set for prescribing an MRA and an alternate order set with option for potassium monitoring should hyperkalemia be a concern. If a patient is hyperkalemic (i.e. K ≥ 5 mEq/L), a link to an order set for prescribing a potassium binder will be provided instead. If a provider feels that the recommended therapy is not indicated for a particular patient, he/she can select an available reason from the list provided within the alert.
Study: NCT06567535

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Navigation and endoscopy
Description: The model was reconstructed using patient CT data, and intraoperative surgery was performed using endoscopy and navigation.
Study: NCT04348292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO
Study: NCT06568068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: training
Description: The intervention group that will receive training determined after randomization; In Stage 1 An introductory meeting will be held, ERGEP will be announced and educational materials will be distributed. Pretest applications will be done. In Stage 2 A week consisting of four weeks and eight sessions on the following topics determined within the scope of ERGEP Trainings planned to be held in two sessions will be given once.~1. Developmental periods (oral, anal, phallic, latent, genital)~2. Physical, psychological and social changes experienced in girls and boys during adolescence~3. Being an adolescent parent and healthy communication~4. Risky behaviors in life and sexual matters during adolescence In Stage 3 At the end of the training, measurement tools will be applied again. In Stage 4 Measuring tools will be repeated after 21 days
Study: NCT04520594

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistant Starch
Description: 7.5 g resistant starch/m2 oral consumption

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral consumption of food-grade cornstarch